title: Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network.
abstract: Mantle cell lymphoma (MCL) is challenging to manage, with a median survival of 3-5 years. While intensive strategies are often appropriate for younger patients, these approaches are often not appropriate for older patients. In 2006, we reported our initial results using modified R-hyperCVAD (rituximab with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) with maintenance rituximab. The complete response rate was 64%, and median progression-free survival (PFS) 37 months. Herein, we update our results, now with a median follow-up of 62 months. The median PFS is unchanged and the median overall survival (OS) is 70 months. The proportion of patients surviving at 5 years is 62%, comparable to studies using intensive strategies in similar patient populations. No late toxicities were noted in our cohort. These long-term results suggest that the modified R-hyperCVAD regimen with maintenance rituximab is an excellent option for older patients with newly diagnosed mantle cell lymphoma.
authors.affiliation: Department of Medicine, University of Wisconsin, Madison, WI, USA.
authors.forename: Vaishalee P
authors.initials: VP
authors.lastname: Kenkre
authors.forename: Walter L
authors.initials: WL
authors.lastname: Long
authors.forename: Jens C
authors.initials: JC
authors.lastname: Eickhoff
authors.forename: Jules H
authors.initials: JH
authors.lastname: Blank
authors.forename: Thomas A
authors.initials: TA
authors.lastname: McFarland
authors.forename: Wayne
authors.initials: W
authors.lastname: Bottner
authors.forename: Hamied
authors.initials: H
authors.lastname: Rezazedeh
authors.forename: Jae E
authors.initials: JE
authors.lastname: Werndli
authors.forename: Howard H
authors.initials: HH
authors.lastname: Bailey
authors.forename: Brad S
authors.initials: BS
authors.lastname: Kahl
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D060828:Induction Chemotherapy; D053208:Kaplan-Meier Estimate; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D060046:Maintenance Chemotherapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010865:Pilot Projects; D012074:Remission Induction; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab